Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).
Epistemonikos ID: 924b083d7be3605e1fb9820cfe7e02500121d3cb
First added on: May 12, 2024